Your browser doesn't support javascript.
loading
SIRT6: therapeutic target for nonalcoholic fatty liver disease.
Zang, Mengwei; Gao, Bin.
Affiliation
  • Zang M; Barshop Institute for Longevity and Aging Studies, Center for Healthy Aging, University of Texas Health San Antonio, San Antonio, TX 78229, USA; Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA; Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX 78229, USA. Electronic address: Zang@uthscsa.edu.
  • Gao B; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
Trends Endocrinol Metab ; 33(12): 801-803, 2022 12.
Article in En | MEDLINE | ID: mdl-36328906
ABSTRACT
Recently, Hou et al. shifted the research focus from the function of nuclear sirtuin (SIRT)6 to that of cytoplasmic SIRT6, which deacetylates and activates long-chain acyl-CoA synthase 5 (ACSL5). Their findings provide mechanistic insight into the role of cytoplasmic SIRT6 in fatty acid oxidation, acting as a therapeutic target for combating nonalcoholic fatty liver disease (NAFLD).
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sirtuins / Non-alcoholic Fatty Liver Disease Limits: Humans Language: En Journal: Trends Endocrinol Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sirtuins / Non-alcoholic Fatty Liver Disease Limits: Humans Language: En Journal: Trends Endocrinol Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article